Key result
Kinin-kallikrein system and chymase linked to COVID-19 hyperinflammation and coagulopathy via RAAS interaction.
Why the study?
Very little attention had been paid to the possible role of the kallikrein-bradykinin system and chymase in the pathogenesis of COVID-19 disease, despite their complex reciprocal interactions with RAAS and involvement in characteristic physiological changes.
Could the inhibition of chymase or blocking BKB1R/BKB2R be effective therapeutic strategies in COVID-19 disease by modulating the kallikrein-bradykinin system and RAAS?
Could the inhibition of chymase or blocking BKB1R/BKB2R be effective therapeutic strategies in COVID-19 disease by modulating the kallikrein-bradykinin system and RAAS?
This review highlights the potential role of the kallikrein-bradykinin system and chymase in COVID-19 pathogenesis, proposing them as novel therapeutic targets.
Answers are grounded in this paper and cite their sources.
May support chymase or bradykinin-receptor inhibition trials in COVID-19; leaves open efficacy without prospective data.
The unique clinical features of COVID-19 disease present a formidable challenge in the understanding of its pathogenesis. Within a very short time, our knowledge regarding basic physiological pathways that participate in SARS-CoV-2 invasion and subsequent organ damage have been dramatically expanded. In particular, we now better understand the complexity of the renin-angiotensin-aldosterone system (RAAS) and the important role of angiotensin converting enzyme (ACE)-2 in viral binding. Furthermore, the critical role of its major product, angiotensin (Ang)-(1-7), in maintaining microcirculatory balance and in the control of activated proinflammatory and procoagulant pathways, generated in this disease, have been largely clarified. The kallikrein-bradykinin (BK) system and chymase are intensively interwoven with RAAS through many pathways with complex reciprocal interactions. Yet, so far, very little attention has been paid to a possible role of these physiological pathways in the pathogenesis of COVID-19 disease, even though BK and chymase exert many physiological changes characteristic to this disorder. Herein, we outline the current knowledge regarding the reciprocal interactions of RAAS, BK, and chymase that are probably turned-on in COVID-19 disease and participate in its clinical features. Interventions affecting these systems, such as the inhibition of chymase or blocking BKB1R/BKB2R, might be explored as potential novel therapeutic strategies in this devastating disorder.
No takes yet. Share an insight, caveat, or question.
Abassi et al. (2021) conducted a review in COVID-19. Chymase inhibitors and bradykinin receptor blockers was evaluated. The kinin-kallikrein system and chymase are deeply interwoven with the renin-angiotensin-aldosterone system and may play a significant role in the hyperinflammation and coagulopathy of COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: